KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to -$1.2 billion.

  • Gsk's Cash from Investing Activities fell 25568.85% to -$1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$5.6 billion, marking a year-over-year decrease of 98563.22%. This contributed to the annual value of -$5.6 billion for FY2025, which is 25532.71% down from last year.
  • Latest data reveals that Gsk reported Cash from Investing Activities of -$1.2 billion as of Q4 2025, which was down 25568.85% from -$2.1 billion recorded in Q3 2025.
  • Over the past 5 years, Gsk's Cash from Investing Activities peaked at $971.9 million during Q2 2024, and registered a low of -$4.9 billion during Q4 2022.
  • In the last 5 years, Gsk's Cash from Investing Activities had a median value of -$891.8 million in 2024 and averaged -$1.3 billion.
  • Per our database at Business Quant, Gsk's Cash from Investing Activities plummeted by 718410.15% in 2022 and then soared by 18056.86% in 2024.
  • Quarter analysis of 5 years shows Gsk's Cash from Investing Activities stood at -$314.1 million in 2021, then tumbled by 1445.3% to -$4.9 billion in 2022, then soared by 64.92% to -$1.7 billion in 2023, then skyrocketed by 146.81% to $797.1 million in 2024, then tumbled by 255.69% to -$1.2 billion in 2025.
  • Its Cash from Investing Activities was -$1.2 billion in Q4 2025, compared to -$2.1 billion in Q3 2025 and -$833.8 million in Q2 2025.